|1.||Kuter, David J: 9 articles (10/2015 - 02/2008)|
|2.||Newland, Adrian: 7 articles (05/2013 - 02/2008)|
|3.||Godeau, Bertrand: 6 articles (12/2015 - 10/2011)|
|4.||Wang, Xuena: 6 articles (12/2015 - 11/2010)|
|5.||Giagounidis, Aristoteles: 6 articles (02/2015 - 07/2012)|
|6.||Hu, Kuolung: 6 articles (06/2014 - 01/2010)|
|7.||Viallard, Jean-François: 6 articles (11/2013 - 02/2008)|
|8.||Stasi, Roberto: 6 articles (11/2013 - 04/2010)|
|9.||Deuson, Robert: 6 articles (10/2013 - 01/2012)|
|10.||Michel, Marc: 5 articles (12/2015 - 09/2011)|
01/20/2010 - "Romiplostim appeared well-tolerated in this study and may be a useful treatment for patients with MDS and thrombocytopenia."
06/15/2014 - "In this study, the authors evaluated the efficacy of romiplostim in patients who had thrombocytopenia with low-risk/intermediate-1-risk MDS. "
11/01/2014 - "He was started on romiplostim with prompt improvement in his thrombocytopenia. "
09/01/2012 - "Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia."
10/20/2011 - "Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program."
06/01/2010 - "In the phase 3 trials, a significantly greater percentage of patients treated with placebo (34%) had bleeding adverse events of moderate or greater severity than did patients treated with romiplostim (15%, P = 0.018). "
10/01/2013 - "Clinical trials have shown that romiplostim increases platelet counts, while reducing the risk of bleeding and, in turn, the need for costly rescue medications. "
12/01/2015 - "The risks for grade ≥3 bleeding (RR 1.92; 95% CI, 0.47-7.95) and thromboembolic events (RR 3.85; 95% CI, 0.53-27.96) were numerically but not significantly higher for romiplostim versus placebo/SOC in patients ≥65 years. "
12/01/2014 - "Overall, the relative risk (RR) of bleeding with romiplostim versus placebo was 0·84 [95% confidence interval (CI): 0·57-1·24]. "
06/15/2014 - "The primary endpoint- the number of clinically significant bleeding events (CSBEs) per patient-had a hazard ratio for romiplostim:placebo of 0.83 (95% confidence interval, 0.66-1.05; P = .13). "
|3.||Thrombocytopenic Purpura (Thrombopenic Purpura)
02/01/2009 - "Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials."
02/02/2008 - "Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial."
09/01/2009 - "A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura."
01/01/2015 - "Treatment of acquired amegakaryocytic thrombocytopenic purpura with romiplostim."
05/01/2014 - "Pseudothrombocytopenia in a patient receiving romiplostim for immune thrombocytopenic purpura."
|4.||Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
12/01/2010 - "[Romiplostim: an advance in the treatment of idiopathic thrombocytopenic purpura]."
09/01/2009 - "Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal."
07/01/2009 - "Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura."
07/01/2015 - "Use of romiplostim in patients with chronic idiopathic thrombocytopenic purpura during perioperative period."
02/01/2010 - "Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option."
|5.||Liver Cirrhosis (Hepatic Cirrhosis)
02/01/2013 - "Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis."
07/01/2011 - "We conclude that romiplostim should be used with precaution in patients with hepatitis C-associated immune thrombocytopenic purpura and advanced liver cirrhosis as the risk for thrombotic complications may increase significantly."
09/01/2014 - "This case report suggests that romiplostim may be effective in the treatment of thrombocytopenic children with liver cirrhosis and portal hypertension, and in eliminating the need for platelet transfusion during the peri-transplant period."
02/01/2013 - "We monitored the efficacy of preoperative romiplostim over 90 days in 35 male patients with chronic hepatitis C, liver cirrhosis and thrombocytopenia secondary to HCV infection. "
07/01/2011 - "We report a case of a patient with Child class B liver cirrhosis with concurrent immune thrombocytopenic purpura that developed portal vein thrombosis under therapy with the thrombopoietin receptor agonist romiplostim. "
|1.||Inosine Triphosphate (ITP)
|3.||Thrombopoietin (c-mpl Ligand)
|6.||Adrenal Cortex Hormones (Corticosteroids)
|7.||serum P-component (CIt)
|10.||4,5,6,7- tetrahydroisoxazolo(4,5- c)pyridin- 3- ol (THPO)
|1.||Drug Therapy (Chemotherapy)
|2.||Platelet Transfusion (Blood Platelet Transfusions)
|4.||Homologous Transplantation (Allograft)